... safety profile of Praluent was consistent with previous trials and no new safety issues were observed Paris and Tarrytown, N.Y. - March 10, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its ...
http://www.globenewswire.com/news-release/2018/03/10/1420167/0/en/Sanofi-Praluent-alirocumab-significantly-reduced-risk-of-cardiovascular-events-in-high-risk-patients-and-was-associated-with-lower-death-rate.html
No comments:
Post a Comment